A tissue‐engineered biocomplex for periodontal reconstruction. A proof‐of‐principle randomized clinical study

• DOI: 10.1111/jcpe.13474
• Publication Date: 2021-04-26T00:40:11Z
• Authors: Danae A. Apatzidou; Athina A. Bakopoulou; Kokkona Kouzi‐Kol...; Vassilis Karagiannis; Antonis Konstanti...
• Keywords: Gingival recession; Platelet-rich fibrin

Abstract Aim To assess the safety/efficacy of a tissue‐engineered biocomplex in periodontal reconstruction. Methods Twenty‐seven intrabony defects were block‐randomized across three treatment groups: Group‐A ( N A = 9) received autologous clinical‐grade alveolar bone marrow mesenchymal stem cells (a‐BMMSCs), seeded into collagen scaffolds, enriched with fibrin/platelet lysate (aFPL). In Group‐B B 10), scaffold/aFPL devoid a‐BMMSCs filled osseous defect. Group‐C C 8) Minimal Access Flap surgery retaining soft tissue wall identically Groups‐A/‐B. Subjects clinically/radiographically assessed before anaesthesia (baseline) and repeatedly over 12 months. Results Quality controls satisfied transplantation. There no adverse healing events. All approaches led to significant clinical improvements p < .001) inter‐group differences. At months, estimated marginal means for all groups as follows: 3.0 (95% CI: 1.9–4.1) mm attachment gain; 3.7 (2.7–4.8) probing pocket depth reduction; 0.7 (0.2–1.3) increase recession. An overall greater mean reduction radiographic Cemento‐Enamel Junction Bottom Defect (CEJ‐BD) distance was found Groups‐A/‐C .023). Conclusion Radiographic evidence fill less pronounced Group‐B, although similar groups. aimed trigger innate potential tissues. Cell‐based therapy is justified reconstruction remains promising selected cases.